BerGenBio ASA: Results for the Fourth Quarter and Full Year 2017
- Tuesday, February 13, 2018, 1:14
- PR Newswire
- Add a comment
BERGEN, Norway, Feb. 13, 2018 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the fourth quarter and full year 2017. A presentation of the…
Source: https://www.prnewswire.com/news-releases/bergenbio-asa-results-for-the-fourth-quarter-and-full-year-2017-300597688.html
About the Author
admin has written 20736 stories on this site.